Page 7 - reflections_dyslipidaemia_newsletter5_2023

REFLECTIONS
Dyslipidaemia
Dyslipidaemia Global Newsletter #6 2023

The authors stress the importance of early assessment of cardiovascular risk and early treatment of dyslipidaemia in women. They
provide a number of key recommendations shown below. Dyslipidaemia

Key recommendations CLINICAL PEARLS FROM THE FACULTY
• Cardiovascular health should be assessed routinely
in women from a young age. This should involve
review of traditional cardiovascular risk-enhancing
factors, sex-specific cardiovascular risk factors, and
gender-related cardiovascular risk factors.

• Elevated lipids (LDL-C, triglycerides, and
lipoprotein(a)) should be treated early with guideline-
recommended therapy.
• As high lipoprotein(a) levels are more common
in women than men after 50 years, repeat
measurement may be indicated.
• Women with FH should be closely followed to WATCH
PROF. SANDIN DISCUSS THE
minimize time off statin therapy due to pregnancy RELEVANCE OF THIS CALL TO
and breastfeeding. Whether treatment targets ACTION FOR CLINICAL PRACTICE.
should be lowered in FH women to compensate for
lost treatment time merits consideration.
• Women with non-obstructive coronary plaque should
receive aggressive risk factor management.
• Further study is needed to understand how sex CLICK HERE
FOR THE LINK TO FULL ARTICLE
hormones and sex chromosomes influence the
pathogenesis of atherosclerosis.

TREATMENT

Statin discontinuation after coronary revascularization.

Yamamoto K, et al. Am J Cardiol. 2023 Oct 3:S0002-9149(23)01029-9.

There is a scarcity of studies evaluating statin adherence and
discontinuation in patients with coronary artery disease (CAD) CREDO-Kyoto PCI/CABG Registry Cohort-3
who underwent coronary revascularization. This long-term, real- • Coronary Revascularization Demonstrating
world follow-up examined the incidence and reasons for statin Outcome Study in Kyoto Percutaneous Coronary
discontinuation in 11,144 patients who underwent first coronary Intervention/Coronary Artery Bypass Grafting
revascularization and were taking statins in the CREDO-Kyoto
Registry Cohort-3. • A physician-initiated, non-company-sponsored,
multicentre registry enrolling consecutive patients
who underwent first coronary revascularization
During a median six years of follow-up, the cumulative incidence
of statin discontinuation was 6.1% at one year, 12.4% at three with PCI or isolated coronary artery bypass grafting
years, 17.4% at five years, and 21.4% at seven years. without combined non-coronary surgery in 22
Japanese centres between January 2011 and
December 2013.

TABLE OF CONTENTS